Suppr超能文献

凝血异常和微血栓形成在脓毒症中的作用:病理生理学、诊断和治疗。

Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment.

机构信息

Department of Emergency and Disaster Medicine, Juntendo University Graduate, School of Medicine, Tokyo, Japan.

Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan; Department of Traumatology and Acute Critical Medicine, Osaka, University Graduate School of Medicine, Osaka, Japan.

出版信息

Arch Med Res. 2021 Nov;52(8):788-797. doi: 10.1016/j.arcmed.2021.07.003. Epub 2021 Jul 31.

Abstract

The diagnostic criteria of overt disseminated intravascular coagulation (DIC) were established by the International Society on Thrombosis and Haemostasis (ISTH) in 2001. Since then, DIC has long been associated with adverse outcomes. However, recent advances in sepsis shed light on the role of coagulation disorders in the progression of sepsis. Currently, inflammation and coagulation are recognized as the two drivers that promote organ dysfunction in sepsis and septic shock. The ISTH has published new diagnostic criteria for improved management, namely sepsis-induced coagulopathy (SIC), in 2017. SIC is a pragmatic scoring system composed of platelet count, prothrombin time, and organ dysfunction score to detect the early-stage of sepsis-associated DIC. Since overt DIC represents an uncompensated coagulation disorder, a two-step approach using SIC and overt DIC criteria is a novel strategy to evaluate the severity and manage this challenging complication. Although there is no globally agreed on anticoagulant therapy for DIC, the Japanese Surviving Sepsis Campaign Guidelines 2020 recommend using antithrombin and recombinant thrombomodulin for sepsis associated DIC. Since research in this area has been previously reported, an international collaborative study is necessary to develop future diagnostic tools and treatment strategies.

摘要

显性弥漫性血管内凝血(DIC)的诊断标准由国际血栓与止血学会(ISTH)于 2001 年建立。自那时以来,DIC 一直与不良预后相关。然而,最近关于脓毒症的研究进展揭示了凝血障碍在脓毒症进展中的作用。目前,炎症和凝血被认为是促进脓毒症和感染性休克器官功能障碍的两个驱动因素。ISTH 于 2017 年发布了新的诊断标准,以改善管理,即脓毒症诱导的凝血障碍(SIC)。SIC 是一个实用的评分系统,由血小板计数、凝血酶原时间和器官功能障碍评分组成,用于检测与脓毒症相关的 DIC 的早期阶段。由于显性 DIC 代表一种未代偿的凝血障碍,因此使用 SIC 和显性 DIC 标准的两步方法是评估严重程度和管理这一具有挑战性的并发症的新策略。尽管对于 DIC 没有全球公认的抗凝治疗方法,但 2020 年日本脓毒症存活运动指南建议使用抗凝血酶和重组血栓调节蛋白治疗与脓毒症相关的 DIC。由于该领域的研究之前已有报道,因此需要进行国际合作研究,以开发未来的诊断工具和治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验